Trial Profile
A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Rigosertib (Primary) ; Cytarabine; Erythropoietin; Filgrastim; Hydroxycarbamide
- Indications Myelodysplastic syndromes
- Focus Registrational; Therapeutic Use
- Acronyms ONTIME
- Sponsors Onconova Therapeutics
- 29 Jun 2020 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Results assessing safety and pharmacokinetics of rigosertib in patients with myelodysplastic syndromes, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 20 Jul 2018 Planned End Date changed from 1 Nov 2018 to 1 Feb 2019.